共 50 条
- [31] An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S585 - S585Rodon, J.Li, J.Xue, J.Diao, Y.Xu, Y.Liu, G.Rao, C.Fan, B.Cheng, Y.Wang, J.
- [32] A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Haydon, Andrew MarkKichenadasse, GanessanKirkwood, John M.Kaufman, Howard E.Buchbinder, Elizabeth IannottiGanju, VinodBarve, Minal A.Jiang, HaifangXu, HuinanZhou, XushaZhu, Huan J.Ni, DongyaoNiu, Jiaxin
- [33] A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Papadopoulos, K. P.Chau, N. G.Patnaik, A.Adriaens, L.Lalani, A. S.Daly, C.Siu, L. L.
- [34] A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lu, MingZhang, PanpanLuo, SuxiaChen, JieYang, JianweiSong, ZhengboLi, YongshengTang, YingZhao, PengLiu, BaoruiLi, JunheHu, ShengZhang, ZhiyeWu, LinSong, LijieFeng, XielinShan, YunfengLiu, TaoCai, ShengliShen, Lin
- [35] Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignanciesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Groves, MorrisHansen, AaronHarb, WaelCurtis, KellyKoga-Yamakawa, ErinaOriguchi, MakotoLi, ZhonggaiIglesias, JoseShaib, WalidSpira, Alexander
- [36] First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Guo, YeWu, LihuaLi, YongWen, JinhuaXue, JunliWang, ZhuoyiLi, PuZhao, WeiLiu, JingfengRao, XiLi, QunXue, LiqiongGe, XiaoxiaoLin, FengjuanTang, WenboZhou, Jiuli
- [37] ARTACUS: AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A580 - A580Luke, JasonMigden, MichaelChai-Ho, WanxingBolotin, DianaWise-Draper, TrishaPoklepovic, AndrewLaux, DouglasKheterpal, MeenalVerschraegen, ClaireCollichio, FrancesLutzky, JoseDaniels, GregoryTsai, KatyNavia, SusanCastro, HenryBommareddy, PraveenPirzkall, AndreaCoffin, Robert
- [38] A FIRST IN-HUMAN, MULTICENTER, OPEN-LABEL, DOSE-FINDING PHASE 1 STUDY OF THE IMMUNE STIMULATOR ANTIBODY CONJUGATE NJH395 IN PATIENTS WITH NONBREAST HER2+ADVANCED MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A230 - A230Janku, FilipHan, Sae-WonDoi, ToshihikoAjani, JafferKuboki, YasutoshiMahling, PingSubramanian, KulandayanPelletier, MarcAskoxylakis, VasileiosSiena, Salvatore
- [39] Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumorsCANCER RESEARCH, 2016, 76Shaheen, MontasserMarkman, BenCarducci, MichaelHurvitz, SaraMahadevan, DarukaKotasek, DusanGoodman, OscarGamelin, ErickChow, VincentJuan, GloriaRasmussen, ErikFriberg, Gregory R.Vogl, Florian D.Desai, Jayesh
- [40] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I studyCANCER RESEARCH, 2024, 84 (07)Beecroft, ClaireGao, BoPark, JohnWilkinson, KateZhang, KarlYan, XiangyunLv, Yuan